TCR2 Therapeutics (NASDAQ: TCRR) reviewed 10-15-2020
Market Cap: $689 Million (USD) Share Price: $20.70 (USD)
Shares outstanding: 33,344,021 as of 3 Aug 2020
Cash & cash equivalents: $49.7 M (USD) as of 30 Jun 2020
Debt: None. Company funds via sales of common and preferred stock
Insiders: Own 5.6% Institutional: 82 own approx. 85% of the float
Website: tcr2.com
Investor Presentations: https://investors.tcr2.com/events-and-presentations/presentations
President and CEO: Garry Menzel, Ph.D. HQs: Cambridge, Mass. USA
Clinical-stage immunotherapy company developing T-cell therapies for patients suffering from cancer. The company’s lead TRuC-T cell product, TC-210, targets solid tumors
TC-210 is being studied in Phase 1/2 trials for patients with non-small-cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma
TCR2 Therapeutics is developing a broad line of T-cell Candidates for Solid and Hematologic Cancers
The company has no current revenue or cash-flow and no licensed products
Loss of $1.32 per share in the six months to 30 Jun 2020. Lost $3.91 per share in the same period of 2019
Has research partnerships with Massachusetts General Hospital, the University of Pittsburgh, Freiburg University, and the Fred Hutchinson Cancer Research Center
Bottom Line:
- TCRR is up +91% in six months and is a darling of institutional investors despite being early in product development
- The company development of T-cell therapies for cancer patients is encouraging. I have had melanoma and squamous cell skin cancers, so this is of personal interest